Your browser doesn't support javascript.
Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates.
Luo, Shengxue; Zhang, Panli; Liu, Bochao; Yang, Chan; Liang, Chaolan; Wang, Qi; Zhang, Ling; Tang, Xi; Li, Jinfeng; Hou, Shuiping; Zeng, Jinfeng; Fu, Yongshui; Allain, Jean-Pierre; Li, Tingting; Zhang, Yuming; Li, Chengyao.
  • Luo S; Department of Pediatrics, Shenzhen Hospital, Southern Medical University, Shenzhen, People's Republic of China.
  • Zhang P; Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People's Republic of China.
  • Liu B; Guangzhou Bai Rui Kang (BRK) Biological Science and Technology Limited Company, People's Republic of China.
  • Yang C; Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People's Republic of China.
  • Liang C; Guangzhou Bai Rui Kang (BRK) Biological Science and Technology Limited Company, People's Republic of China.
  • Wang Q; Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People's Republic of China.
  • Zhang L; Guangzhou Bai Rui Kang (BRK) Biological Science and Technology Limited Company, People's Republic of China.
  • Tang X; School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, People's Republic of China.
  • Li J; Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People's Republic of China.
  • Hou S; Guangzhou Bai Rui Kang (BRK) Biological Science and Technology Limited Company, People's Republic of China.
  • Zeng J; Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People's Republic of China.
  • Fu Y; Guangzhou Bai Rui Kang (BRK) Biological Science and Technology Limited Company, People's Republic of China.
  • Allain JP; Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People's Republic of China.
  • Li T; Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People's Republic of China.
  • Zhang Y; Department of Infection, The First People's Hospital of Foshan, Foshan, People's Republic of China.
  • Li C; Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People's Republic of China.
Emerg Microbes Infect ; 10(1): 1002-1015, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1231006
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
ABSTRACTCOVID-19 vaccines are being developed urgently worldwide. Here, we constructed two adenovirus vectored COVID-19 vaccine candidates of Sad23L-nCoV-S and Ad49L-nCoV-S carrying the full-length gene of SARS-CoV-2 spike protein. The immunogenicity of two vaccines was individually evaluated in mice. Specific immune responses were observed by priming in a dose-dependent manner, and stronger responses were obtained by boosting. Furthermore, five rhesus macaques were primed with 5 × 109 PFU Sad23L-nCoV-S, followed by boosting with 5 × 109 PFU Ad49L-nCoV-S at 4-week interval. Both mice and macaques well tolerated the vaccine inoculations without detectable clinical or pathologic changes. In macaques, prime-boost regimen induced high titers of 103.16 anti-S, 102.75 anti-RBD binding antibody and 102.38 pseudovirus neutralizing antibody (pNAb) at 2 months, while pNAb decreased gradually to 101.45 at 7 months post-priming. Robust T-cell response of IFN-γ (712.6 SFCs/106 cells), IL-2 (334 SFCs/106 cells) and intracellular IFN-γ in CD4+/CD8+ T cell (0.39%/0.55%) to S peptides were detected in vaccinated macaques. It was concluded that prime-boost immunization with Sad23L-nCoV-S and Ad49L-nCoV-S can safely elicit strong immunity in animals in preparation of clinical phase 1/2 trials.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunization, Secondary / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Animals / Female / Humans / Male Language: English Journal: Emerg Microbes Infect Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunization, Secondary / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Animals / Female / Humans / Male Language: English Journal: Emerg Microbes Infect Year: 2021 Document Type: Article